Bridging the Gap Between Participants and Clinical Trials
GS-US-563-5925: People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir
CONDITION
Other
GENDER
All
AGE GROUP
From 18
and above
STATUS
Active, not recruiting
A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir (B/F/TAF)